Sector ratings Perspective Therapeutics, Inc.

Stocks

Delayed NYSE 21:00:00 04/09/2026 BST			5-day change	1st Jan Change
3.130 ^USD	+0.32%		+0.64%	+13.82%

08-19	BMO Capital Initiates Perspective Therapeutics at Outperform	MT
08-14	BofA Securities Adjusts Perspective Therapeutics Price Target to $5 From $6	MT

Sector:

Location:

X axis:

Main competitors

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Capi.($)	Investor	ESG MSCI	Fundamentals	Global Valuation
PERSPECTIVE THERAPEUTICS, INC.	357M	-	BBB	-	-
LONZA GROUP AG	48.93B		AAA
REVOLUTION MEDICINES, INC.	45.01B	-	B	-	-
IQVIA HOLDINGS INC.	44.07B		AAA
BEONE MEDICINES AG	40.73B		-
CELLTRION, INC.	33.52B		A
ASCENDIS PHARMA A/S	17.77B	-	-	-	-
MEDPACE HOLDINGS, INC.	16.5B		BBB
EUROFINS SCIENTIFIC SE	14.67B		AA
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	13.77B		AA
ICON PUBLIC LIMITED COMPANY	12.72B		AAA
TEMPUS AI, INC.	11.66B		A		-
BIO-TECHNE CORPORATION	11.36B		AA
ABIVAX	9.78B	-	BBB	-	-
PHARMARON BEIJING CO., LTD.	10.39B		AA
PRAXIS PRECISION MEDICINES, INC.	9.82B	-	B	-	-
KYMERA THERAPEUTICS, INC.	9.76B	-	BBB	-	-
IONIS PHARMACEUTICALS, INC.	9.65B	-	A	-	-
PROTAGONIST THERAPEUTICS, INC.	9.43B		BB		-
QIAGEN N.V.	8.99B		AAA
Average	18.95B		A
Weighted average by Cap.			A